# Dietary fiber and soy protein-based microbiome metabolites for IBD prevention

> **NIH NIH R01** · UNIVERSITY OF MICHIGAN AT ANN ARBOR · 2024 · $648,836

## Abstract

Summary
The precise etiology of inflammatory bowel disease (IBD) remains unknown. Despite identification of >100
human genetic polymorphisms that are thought to play a role in IBD, genetic predisposition typically explains
only a fraction of disease risk. Important contributions for environmental factors—including diet and the gut
microbiota—have become prominent suspects as additional disease drivers. However, the functional
interconnections between these potential contributors remain unknown. Using a gnotobiotic mouse model, in
which animals were colonized with a synthetic human gut microbiota composed of fully sequenced and
metabolically characterized commensal bacteria, we have begun to elucidate the mechanistic interactions
between dietary fiber, the gut microbiota and the colonic mucus barrier, which serves as a primary defense
against encroachment by intestinal bacteria. During dietary fiber deficiency, the gut microbiota resorts to host-
secreted mucus glycoproteins as a nutrient source, leading to erosion of the mucus layer. Dietary fiber
deprivation, together with a fiber-deprived, mucus-eroding microbiota, promotes greater epithelial access and
lethal colitis by the mucosal pathogen, Citrobacter rodentium. More strikingly, when this same synthetic
microbiota is assembled in mice deficient in interleukin 10 (IL-10), a cytokine for which loss of function defects
have been associated with human IBD, animals develop lethal spontaneous inflammation in the absence of an
overt pathogen, but only on a low fiber diet. Our work has therefore revealed functional interconnections
between diet, the gut microbiota, mucosal barrier function and spontaneous IBD development. Our central
hypothesis is that there is a dynamic balance between fiber- and mucus-degrading bacteria, such that in low
fiber conditions the mucus layer is increasingly eroded resulting in temporal disease progression that can be
ameliorated by preventative or therapeutic fiber consumption or other bacterial metabolites that counterbalance
inflammation. The proposed work will extend the findings outlined above by first measuring the respective
contributions of mucin-degrading bacteria and their functions towards eroding the mucosal barrier and
precipitating inflammation. We have already established that addition of several pure fibers to our fiber
deficient diet reduces disease and have fortuitously discovered that inclusion of soy (but not milk) protein also
reduces disease in part by promoting production of the branched chain fatty acid isobutyrate. Isobutyrate is
produced from L-valine and our hypothesis is that soy protein delivers a peptide-based source of this amino
acid to the colon for bacterial metabolism. Because isobutyrate is a poorly studied metabolite, we will
investigate its microbial source(s) and mechanism of action in dampening host inflammation. We anticipate
that our findings will provide functional insight into the constellation of genetic and environmental tri...

## Key facts

- **NIH application ID:** 10764925
- **Project number:** 5R01DK118024-06
- **Recipient organization:** UNIVERSITY OF MICHIGAN AT ANN ARBOR
- **Principal Investigator:** GRACE Y. CHEN
- **Activity code:** R01 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2024
- **Award amount:** $648,836
- **Award type:** 5
- **Project period:** 2018-07-03 → 2026-12-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10764925

## Citation

> US National Institutes of Health, RePORTER application 10764925, Dietary fiber and soy protein-based microbiome metabolites for IBD prevention (5R01DK118024-06). Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/grant/nih/10764925. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
